Targeting PARP-1 with metronomic therapy as a new approach to modulate MDSC function and enhance anti-PD1 immunotherapy in colon cancer

Authors

Salome Valentina Ibba, LSU Health Sciences Center - New Orleans
Mohamed Ghonim, LSU Health Sciences Center - New Orleans
Abdelmetalab Tarhuni, LSU Health Sciences Center - New Orleans
Matthew Dean, LSU Health Sciences Center - New OrleansFollow
Hamid Boulares, LSU Health Sciences Center - New OrleansFollow
Augusto Ochoa, LSU Health Sciences Center - New OrleansFollow
Youssef Errami, LSU Health Sciences Center - New Orleans
Ali Elbahraway, LSU Health Sciences Center - New Orleans
Ilyes Benslimane, LSU Health Sciences Center - New Orleans
Dorota Wyczechowska, LSU Health Sciences Center - New OrleansFollow
Luis Del Valle, LSU Health Sciences Center - New OrleansFollow
Amir Al-Khami, Tanta University, Tanta, Egypt
Hanh Luu, LSU Health Sciences Center - New Orleans

Document Type

Conference Proceeding

Publication Date

11-1-2019

Publication Title

Journal for ImmunoTherapy of Cancer

Abstract

34th Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer - Part 1, November 6 - 10, 2019, National Harbor, MD

First Page

272

Volume

7

Issue

Supplement 1

Comments

Abstract Number P500

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Recommended Citation

Ibba, Salome Valentina; Ghonim, Mohamed; Tarhuni, Abdelmetalab; Dean, Matthew; Boulares, Hamid; Ochoa, Augusto; Errami, Youssef; Elbahraway, Ali; Benslimane, Ilyes; Wyczechowska, Dorota; Del Valle, Luis; Al-Khami, Amir; and Luu, Hanh, "Targeting PARP-1 with metronomic therapy as a new approach to modulate MDSC function and enhance anti-PD1 immunotherapy in colon cancer" (2019). School of Medicine Faculty Publications. 2347.
https://digitalscholar.lsuhsc.edu/som_facpubs/2347
10.1186/s40425-019-0763-1